HLB Pharmaceutical Co., Ltd. (KOSDAQ: 047920)
South Korea
· Delayed Price · Currency is KRW
27,000
+350 (1.31%)
Sep 11, 2024, 1:56 PM KST
HLB Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2019 | FY 2018 | FY 2017 |
| Sep '24 Sep 10, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| Market Capitalization | 377,738 | 75,194 | 58,507 | 80,206 |
| Market Cap Growth | 28.52% | 28.52% | -27.05% | - |
| Enterprise Value | 77,595 | 77,595 | 62,071 | - |
| Last Close Price | 26900.00 | 5430.00 | 4225.00 | 6420.00 |
| PE Ratio | - | 159.09 | -8.10 | -14.11 |
| PS Ratio | 10.32 | 2.08 | 2.85 | 5.16 |
| PB Ratio | 20.81 | 4.20 | 3.44 | 4.77 |
| P/FCF Ratio | -1716.81 | -1716.81 | -20.37 | -26.55 |
| P/OCF Ratio | 55.56 | 55.56 | -32.92 | -102.27 |
| EV/Sales Ratio | 2.15 | 2.15 | 3.02 | - |
| EV/EBITDA Ratio | 25.19 | 25.19 | -13.25 | - |
| EV/EBIT Ratio | 53.85 | 53.85 | -10.65 | - |
| EV/FCF Ratio | -1771.63 | -1771.63 | -21.61 | - |
| Debt / Equity Ratio | 0.74 | 0.74 | 0.45 | 0.89 |
| Debt / EBITDA Ratio | 4.28 | 4.28 | - | - |
| Debt / FCF Ratio | -301.34 | -301.34 | -2.68 | -4.95 |
| Asset Turnover | 0.88 | 0.88 | 0.54 | - |
| Inventory Turnover | 3.27 | 3.27 | 3.13 | - |
| Quick Ratio | 1.01 | 1.01 | 0.94 | 1.01 |
| Current Ratio | 1.26 | 1.26 | 1.31 | 1.31 |
| Return on Equity (ROE) | 2.71% | 2.71% | -41.77% | - |
| Return on Assets (ROA) | 2.19% | 2.19% | -9.55% | - |
| Return on Capital (ROIC) | 3.23% | 3.23% | -12.90% | - |
| Earnings Yield | 0.13% | 0.63% | -12.07% | -6.79% |
| FCF Yield | -0.01% | -0.06% | -4.91% | -3.77% |
| Buyback Yield / Dilution | -2.30% | -2.30% | -13.08% | - |
| Total Shareholder Return | -2.30% | -2.30% | -13.08% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.